- Novartis Profits Soar as Vasella Steps Down as CEO (PharmaTimes)
- MHRA Warns Of Internet Sales Of Counterfeit Alli (Pharmaceutical Business Review)
- Novartis Incoming CFO: No Plan For New Cost-Cutting Program (The Wall Street Journal)
- Bristol-Myers Squibb announces EU approval of ORENCIA (Zenopa)
- Novo Nordisk Gets US Approval for Victoza but with Warning (PharmaTimes)
- Bayer to Discontinue Phase II Clinical Trial for Long-Acting Recombinant Factor VIII (World Pharma News)
- Alizé Pharma Signs Research Collaboration and License Option Agreement With Lilly (PharmaLive)
- Researchers Simplify Dangerously Confusing Warnings On Prescription Bottles (Medical News Today)
- AstraZeneca Ignored Seroquel Weight Gain Data, Claims Ex-Employee (PharmaTimes)
- Was the Threat of H1N1 Flu Exaggerated? (Time Magazine)
- China Tightening Worries Spook Investors, Hit Markets (BNet)
SUBSCRIBE